Alternatively, pituitary tumors are generally classified as being benign, including the series in the current study, so there may be a regulatory mechanism in MSH6/2 and PD-L1 mRNA expressions in benign tumors as NFPAs that differs from that in malignant tumors. This evidence concerns the gene MSH6 and benign neoplasm.